Fragile X syndrome: an update on developing treatment modalities
| Autor: | Aileen Healy, Timothy D. Ocain, Roger Rush |
|---|---|
| Rok vydání: | 2011 |
| Předmět: |
medicine.medical_specialty
Baclofen Physiology Cognitive Neuroscience Receptor Metabotropic Glutamate 5 Treatment outcome Receptors Metabotropic Glutamate Biochemistry Allosteric Regulation Intellectual disability Drug Discovery Medicine Animals Humans Psychiatry business.industry Cognition Cell Biology General Medicine medicine.disease Fragile X syndrome Treatment Outcome Treatment modality Fragile X Syndrome business Central Nervous System Agents |
| Zdroj: | ACS chemical neuroscience. 2(8) |
| ISSN: | 1948-7193 |
| Popis: | Intellectual disability (ID; mental retardation) is considered an immutable condition. Current medical practices are aimed at relieving symptoms and not at altering the underlying cognitive deficits. Scientific advancements from the past decade have led to the exciting possibility that ID may now be treatable. Moreover, pharmaceutical therapies targeting the most common form of inherited ID, Fragile X syndrome (FXS), may become the new benchmark for central nervous system (CNS) drug discovery: seeking cures for neurodevelopmental disorders. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|